Tulex Pharmaceuticals Inc., DBA Tulex Pharmaceuticals Inc.

États‑Unis d’Amérique

Commandez votre montre hebdomadaire Tulex Pharmaceuticals Inc., DBA Tulex Pharmaceuticals Inc.
Quantité totale PI 20
Rang # Quantité totale PI 76 191
Note d'activité PI 2,3/5.0    26
Rang # Activité PI 30 098
Classe Nice dominante Services scientifiques, technolo...

Brevets

Marques

12 1
2 0
5 0
0
 
Dernier brevet 2025 - Desmopressin oral compositions
Premier brevet 2019 - Atovaquone nanoparticulate compo...
Dernière marque 2015 - TULEX PHARMACEUTICALS
Première marque 2015 - TULEX PHARMACEUTICALS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 Invention Desmopressin oral compositions. Provided herein are desmopressin oral liquid formulations. Also ...
Invention Compositions and methods for treating epilepsy, seizures and other conditions. Compositions are ...
2024 Invention Desmopressin oral compositions. Provided herein are desmopressin oral liquid formulations. Also p...
Invention Ready to use non-aqueous solutions of lamotrigine. Disclosed are ready to use non-aqueous soluti...
Invention Ready to use non-aqueous solutions of lamotrigine. Disclosed are ready to use non-aqueous solutio...
Invention Compositions and methods for treating epilepsy, seizures and other conditions. Compositions are p...
2023 Invention Novel compositions. The present disclosure is directed to coated drug ion exchange particles and...
Invention Novel compositions. The present disclosure is directed to coated drug ion exchange particles and ...
2022 Invention Extended-release compositions comprising atomoxetine. The present disclosure provides extended r...
Invention Extended-release compositions comprising atomoxetine. The present disclosure provides extended re...
2019 Invention Atovaquone nanoparticulate compositions. A nanoparticle ATQ composition is provided which has goo...
2015 P/S Development of pharmaceutical preparations and medicines